Page last updated: 2024-12-08

1-(2,6-dimethylphenoxy)-2-(3,4-dimethoxyphenylethylamino)propane

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

You're asking about a molecule with a rather complex structure and name. Let's break it down:

**1-(2,6-dimethylphenoxy)-2-(3,4-dimethoxyphenylethylamino)propane**

* **Structure:** This is a complex organic molecule with multiple functional groups:
* **Phenoxy:** An aromatic ring with an oxygen atom directly attached to the ring. There are two of these (2,6-dimethylphenoxy) in the molecule.
* **Dimethoxy:** Two methoxy (CH3O-) groups attached to the aromatic ring. There are two of these (3,4-dimethoxy) in the molecule.
* **Ethylamino:** An ethyl group (CH3CH2-) connected to an amino group (-NH2).
* **Propane:** A three-carbon chain.
* **The numbers:** Indicate the position of the substituents on the aromatic rings and the propane chain.

* **Potential Importance for Research:** Based on its structure, this molecule likely belongs to a class of compounds called **beta-blockers**. These are medications commonly used to treat conditions like high blood pressure, irregular heartbeats, and migraines.

**Why beta-blockers are important:**

* **Cardiovascular Disease:** Beta-blockers work by blocking the effects of adrenaline (epinephrine) on the heart and blood vessels. This helps to lower heart rate, reduce blood pressure, and decrease the workload on the heart. They are essential for managing and preventing cardiovascular diseases.
* **Other Medical Conditions:** Beta-blockers have been shown to be effective in treating conditions beyond cardiovascular issues, such as migraine headaches, essential tremor, and anxiety.

**Key Points:**

* The specific molecule you mentioned might be a novel beta-blocker candidate or a derivative of an existing one.
* Research on this molecule could focus on:
* **Pharmacological Activity:** Determining its effectiveness in blocking beta-adrenergic receptors and its potential therapeutic benefits.
* **Safety and Toxicity:** Evaluating its side effects and potential risks.
* **Pharmacokinetics:** Understanding how the body absorbs, distributes, metabolizes, and eliminates the compound.

**Important Note:** I cannot provide specific information about the research significance of this exact molecule without further context. Its importance is likely tied to its potential pharmacological properties and how it compares to other known beta-blockers.

Cross-References

ID SourceID
PubMed CID163906
CHEMBL ID184014
MeSH IDM0160854

Synonyms (10)

Synonym
bdbm50151862
[2-(3,4-dimethoxy-phenyl)-ethyl]-[2-(2,6-dimethyl-phenoxy)-1-methyl-ethyl]-amine
dmpeap
CHEMBL184014 ,
113346-50-2
n-[2-(3,4-dimethoxyphenyl)ethyl]-1-(2,6-dimethylphenoxy)propan-2-amine
1-(2,6-dimethylphenoxy)-2-(3,4-dimethoxyphenylethylamino)propane hcl
1-(2,6-dimethylphenoxy)-2-(3,4-dimethoxyphenylethylamino)propane
benzeneethanamine, n-(2-(2,6-dimethylphenoxy)-1-methylethyl)-3,4-dimethoxy-
DTXSID60921045
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Potassium voltage-gated channel subfamily H member 2Homo sapiens (human)IC50 (µMol)6.10000.00091.901410.0000AID240820
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (22)

Processvia Protein(s)Taxonomy
regulation of heart rate by cardiac conductionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of heart rate by hormonePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of membrane potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
positive regulation of DNA-templated transcriptionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion homeostasisPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cardiac muscle contractionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of ventricular cardiac muscle cell membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cellular response to xenobiotic stimulusPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
ventricular cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane depolarization during action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of heart rate by cardiac conductionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion export across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during ventricular cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
negative regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
positive regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
negative regulation of potassium ion export across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion import across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (12)

Processvia Protein(s)Taxonomy
transcription cis-regulatory region bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
inward rectifier potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
delayed rectifier potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
ubiquitin protein ligase bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
identical protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
protein homodimerization activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
C3HC4-type RING finger domain bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activity involved in cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
scaffold protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (5)

Processvia Protein(s)Taxonomy
plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cell surfacePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
perinuclear region of cytoplasmPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel complexPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
inward rectifier potassium channel complexPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID240820Inhibitory concentration against IKr potassium channel2004Bioorganic & medicinal chemistry letters, Sep-20, Volume: 14, Issue:18
The pharmacophore hypotheses of I(Kr) potassium channel blockers: novel class III antiarrhythmic agents.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (36)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (2.78)18.7374
1990's5 (13.89)18.2507
2000's21 (58.33)29.6817
2010's6 (16.67)24.3611
2020's3 (8.33)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.70

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.70 (24.57)
Research Supply Index3.64 (2.92)
Research Growth Index5.34 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.70)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (2.78%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other35 (97.22%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]